Agilent Technologies and Roche have signed an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services.   Clients using NimbleGen microarrays for all applications, including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation and gene expression can transition to Agilent arrays, effective immediately. According to the companies, the similarities of the technologies and ...